FOXO3 and osteosarcoma: While we cannot rule out that the cellular context in the osteosarcoma-derived cell line limits the impact of the MAPK/ERK pathway on FOXO3, the MAPK inhibitors used in the experiments have been seen to affect MAPK signaling in U2OS cells.